COME TI POSSIAMO AIUTARE?

Centralino
095 7339000

Se hai bisogno di maggiori informazioni contattaci telefonicamente

Prenotazioni
095 7339000

Prenota una visita in privato o con assicurazione telefonicamente, oppure direttamente online

Contabilità
095 73390119
Direzione sanitaria
095 73390203
Direzione amministrativa
095 73390668
Ufficio stampa e comunicazione
095 73390764

Dott. Alessandro Russo

Prenota una visita
  • Area Medica
    Unità Operativa di Oncologia Medica e Oncoematologia
  • Ruolo
    Medico specialista in Oncologia Medica

Io in Humanitas

Unità
Unità Operativa di Oncologia Medica e Oncoematologia
Ruolo in Ospedale
Medico specialista in Oncologia Medica
Aree mediche di interesse
Trattamento delle neoplasie toraco-polmonari e dei tumori cerebrali primitivi. L’attività di ricerca clinica è incentrata principalmente al trattamento delle neoplasie toraciche con responsabilità del percorso diagnostico-terapeutico e delle sperimentazioni cliniche nel ruolo di principal investigator di numerosi trials clinici di fase II/III. Membro di numerose società scientifiche nazionali ed internazionali, tra cui: International Society of Liquid Biopsy (ISLB); International Association for the Study of Lung Cancer (IASLC); Associazione Italiana di Oncologia Toracica (AIOT); Associazione Italiana di Oncologia Medica (AIOM); European Society For Medical Oncology (ESMO).

Esperienze precedenti

Ultima esperienza lavorativa
Dal 2020 al 2024
UOC di Oncologia Medica dell’A.O. Papardo – Messina
– Responsabile dell’ambulatorio delle patologie toraco-polmonari presso l’UOC di Oncologia Medica dell’A.O. Papardo di Messina e membro del relativo Gruppo Oncologico Multidisciplinare (G.O.M.). – L’attività di ricerca clinica è incentrata principalmente al trattamento delle neoplasie toraciche con responsabilità del percorso diagnostico-terapeutico e delle sperimentazioni cliniche nel ruolo di sub-investigator e/o principal investigator

Penultima esperienza lavorativa
2019
Marlene and Stewart Greenebaum Comprehensive Cancer Center, Program
in Thoracic Oncology and Drug Development, at the University of Maryland School of Medicine – Baltimora (USA)
– Visiting Researcher presso il Marlene and Stewart Greenebaum Comprehensive Cancer Center, Program in Thoracic Oncology and Drug Development, at the University of Maryland School of Medicine, Baltimore, USA (Tutor: Prof. Christian Rolfo). Durante tale periodo, l’attività di ricerca clinica e traslazionale è stata svolta attraverso la partecipazione alle attività di ricerca clinica-traslazionale del gruppo del Prof. C. Rolfo, con particolare riferimento al ruolo degli esosomi tumorali e di altri biomarcatori circolanti nella valutazione della risposta agli immune checkpoint inhibitors nel NSCLC e all’individuazione di eventuali differenze etniche nell’attività di tali agenti.

Formazione

Laurea
Laurea in Medicina e Chirurgia
Anno di laurea: 2010
Università degli Studi di Messina

Prima specializzazione
Oncologia Medica
Anno: 2016
Università degli Studi di Messina

Seconda specializzazione
Dottorato di Ricerca (XXXII ciclo) in Biotecnologie Mediche e Chirurgiche
Anno: 2019
Università degli Studi di Messina

Pubblicazioni ed attività scientifica

A) Pubblicazioni scientifiche su riviste internazionali

  1. de Miguel-Perez D, Arroyo-Hernandez M, La Salvia S, Gunasekaran M, Pickering EM, Avila S, Gebru E, Becerril-Vargas E, Monraz-Perez S, Saharia K, Grazioli A, McCurdy MT, Frieman M, Miorin L, Russo A, Cardona AF, García-Sastre A, Kaushal S, Hirsch FR, Atanackovic D, Sahoo S, Arrieta O, Rolfo C. Extracellular vesicles containing SARS-CoV-2 proteins are associated with multi-organ dysfunction and worse outcomes in patients with severe COVID-19. J Extracell Vesicles. 2024 Nov;13(11):e70001. doi: 10.1002/jev2.70001. PMID: 39558820; PMCID: PMC11574309. [IF 2022: 15.5]
  2. Pisapia P, Russo A, De Luca C, Pepe F, Drago F, Rolfo C, Troncone G, Malapelle U (2024). The relevance of the reference range for EGFR testing in non-small cell lung cancer patients. Lung Cancer: 108002. https://doi.org/10.1016/j.lungcan.2024.108002 [IF 2022: 4.5]
  3. Rolfo C, Russo A. The Next Frontier for Colorectal Cancer Screening: Blood-Based Tests. Cancer Res. 2024 Oct 1;84(19):3128-3129. doi: 10.1158/0008-5472.CAN-24-1620. PMID: 39350663. [IF 2022: 12.701]
  4. Ranganathan S, Reddy A, Russo A, Malepelle U, Desai A. Double Agents in Immunotherapy: Unmasking the Role of Antibody Drug Conjugates in Immune Checkpoint Targeting. Crit Rev Oncol Hematol. 2024 Aug 5:104472. doi: 10.1016/j.critrevonc.2024.104472. Epub ahead of print. PMID: 39111458. [IF 2022: 6.2]
  5. Arrieta O, Arroyo-Hernández M, Soberanis-Piña PD, Viola L, Del Re M, Russo A, de Miguel-Perez D, Cardona AF, Rolfo C. Facing an un-met need in lung cancer screening: the never smokers. Crit Rev Oncol Hematol. 2024 Jul 6:104436. doi: 10.1016/j.critrevonc.2024.104436. Epub ahead of print. PMID: 38977146. [IF 2022: 6.2]
  6. Muscolino P, Scimone C, Sapuppo E, Micali V, Vasta I, Santacaterina A, Santarpia M, Russo A. Gefitinib resensitization after a TKI-free interval in osimertinib resistant non-small cell lung cancer: A glimpse of hope in time of crisis? Clin Lung Cancer. 2024 Jun 10:S1525-7304(24)00112-8. doi: 10.1016/j.cllc.2024.06.003 [IF 2022: 3.6]
  7. Rolfo C, Russo A. The Chemoimmunotherapy Revolution in Resectable NSCLC-The Times They Are A-Changin’. JAMA Oncol. 2024 Mar 21. doi: 10.1001/jamaoncol.2024.0043. Epub ahead of print. PMID: 38512287. [IF 2022: 33.01]
  8. de Miguel-Perez D, Ak M, Mamindla P, Russo A, Zenkin S, Ak N, Peddagangireddy V, Lara-Mejia L, Gunasekaran M, Cardona AF, Naing A, Hirsch FR, Arrieta O, Colen RR, Rolfo C. Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC. J Exp Clin Cancer Res. 2024 Mar 15;43(1):81. doi: 10.1186/s13046-024-02997-x. PMID: 38486328; PMCID: PMC10941547. [IF 2022: 11.3]
  9. Russo A, Muscolino P, Rolfo C. LIBRETTO-431: Is it time to reconsider randomized phase 3 trials for uncommon oncogenic drivers in non-small-cell lung cancer? Med. 2024;5(2):112-114. doi:10.1016/j.medj.2023.12.002 [IF 2022: 17]
  10. Rolfo C, Russo A. Navigating into a stormy sea: liquid biopsy enters peri-operative management in early-stage non-small cell lung cancer. Annals of Oncology. 2024;35(2):147-149. doi:10.1016/j.annonc.2023.12.010 [IF 2022: 50.5]
  11. Russo A, Lee JK, Pasquina LW, Del Re M, Dilks HH, Murugesan K, Madison RW, Lee Y, Schrock AB, Comment L, Dietrich M, Oxnard GR, Rolfo C. Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment. JCO Precis Oncol. 2024 Jan;8:e2300535. doi: 10.1200/PO.23.00535. PMID: 38295321. [IF 2022: 4.6]
  12. Rolfo C, Del Re M, Russo A. Exploring the epigenetic susceptibility mechanisms of lung cancer through DNA methylation markers. Cancer. 2024 Jan 18. doi: 10.1002/cncr.35203. Epub ahead of print. PMID: 38236782. [IF 2022: 6.2]
  13. Del Re M, Russo A, Rolfo C. Changing the way we treat KRAS G12C non-small cell lung cancers. AME Clin Trials Rev 2024. https://dx.doi.org/10.21037/actr-23-12
  14. Longo V, Della Corte CM, Russo A, Spinnato F, Ambrosio F, Ronga R, Marchese A, Del Giudice T, Sergi C, Casaluce F, Gilli M, Montrone M, Gristina V, Sforza V, Reale ML, Di Liello R, Servetto A, Lipari H, Longhitano C, Vizzini L, Manzo A, Cristofano A, Paolelli L, Nardone A, De Summa S, Perrone A, Bisceglia C, Derosa C, Nardone V, Viscardi G, Galetta D and Vitiello F (2024) Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy. Front. Immunol. 14:1289434. doi: 10.3389/fimmu.2023.1289434 [IF 2022: 7.3]
  15. Li J, Huang K, Ji H, Qian J, Lu H, Zhang Y, Russo A, Romero A, Urbanska EM, Tabbò F, Zhao X, Chu T. Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (ALK) rearrangements and co-existing alterations—a retrospective cohort study. Transl Lung Cancer Res 2023;12(12):2505-2519. doi: 10.21037/tlcr-23-658. [IF 2022: 4]
  16. Gouda MA, Janku F, Wahida A, Buschhorn L, Schneeweiss A, Abdel Karim N, De Miguel Perez D, Del Re M, Russo A, Curigliano G, Rolfo C, Subbiah V. Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST). Ann Oncol. 2024. https://doi.org/10.1016/j.annonc.2023.12.007 [IF 2022: 50.5]
  17. Passiglia F, Reale ML, Lo Russo G, Pasello G, Minuti G, Bulotta A, Galetta D, Pelizzari G, Sini C, Bria E, Roca E, Pilotto S, Genova C, Metro G, Citarella F, Chiari R, Cortinovis D, Delmonte A, Russo A, Tiseo M, Cerea G, Carta A, Scotti V, Vavalà T, Brambilla M, Buffoni L, Buosi R, Catania C, Gori S, Grisanti S, Agustoni F, Garbo E, Malapelle U, Novello S Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program. Lung Cancer 2024. https://doi.org/10.1016/j.lungcan.2023.107444 [IF 2022: 5.3]
  18. Scimone C, Pepe F, Russo G, Palumbo L, Ball G, Morel P, Russo A, Troncone G, Malapelle U. Technical evaluation of a novel digital PCR platform for detecting EGFR/KRAS mutations in NSCLC archived plasma specimens. The Journal of Liquid Biopsy 2024: 100133. https://doi.org/10.1016/j.jlb.2023.100133
  19. Rolfo C, Russo A. In search of lost biomarker for immunotherapy in small-cell lung cancer. Clin Cancer Res. 2023 Dec 12. doi: 10.1158/1078-0432.CCR-23-3087. Epub ahead of print. PMID: 38085269. [IF 2022: 11.5]
  20. de Miguel-Perez D, Pickering EM, Malapelle U, Grier W, Pepe F, Pisapia P, Russo G, Pinto JA, Russo A, Troncone G, Culligan MJ, Scilla KA, Mehra R, Mohindra P, Arrieta O, Cardona AF, Del Re M, Sachdeva A, Hirsch FR, Wolf A, Friedberg JS, Rolfo C. Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.113457 [IF 2022: 8.4]
  21. de Miguel-Perez D, Ortega FG, Tejada RG, Martínez-Única A, Peterson CB, Russo A, Gunasekaran M, Cardona AF, Amezcua V, Lorente JA, Expósito Hernández J, Rolfo C, Serrano MJ. Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer. Biomark Res. 2023 Nov 15;11(1):98. doi: 10.1186/s40364-023-00544-y. PMID: 37968730. [IF 2022: 11.1]
  22. Rolfo C, Russo A. Brave new world of cfDNA-omics for early cancer detection. J Immunother Cancer. 2023 Sep;11(9):e006309. doi: 10.1136/jitc-2022-006309. PMID: 37696620. [IF 2022: 10.9]
  23. Rolfo C, Del Re M, Russo A. Empower the potential of trastuzumab deruxtecan with novel combinations. Clin Cancer Res. 2023 Sep 1. doi: 10.1158/1078-0432.CCR-23-1700. Epub ahead of print. PMID: 37656059. [IF 2022: 11.5]
  24. Catania C, Filippi AR, Sangalli C, Piperno G, Russano M, Greco C, Scotti V, Proto C, Bennati C, Di Pietro Paolo M, Platania A, Olmetto E, Agustoni F, Teodorani N, Agbaje V, Russo A. New options and open issues in the management of unresectable stage III and in early-stage NSCLC: a report from an expert panel of Italian medical and radiation oncologists – INTERACTION GROUP. Crit Rev Oncol Hematol. 2023 Aug 24:104108. doi: 10.1016/j.critrevonc.2023.104108. Epub ahead of print. PMID: 37633350. [IF 2022: 6.2]
  25. Russo A, Scilla KA, Mehra R, Gittens A, McCusker MG, de Miguel-Perez D, Gomez JE, Peleg A, Del Re M, Rolfo CD. Tracking clonal evolution of EGFR-mutated non-small cell lung cancer through liquid biopsy: Management of C797S acquired mutation. Clinical Lung Cancer (2023), doi: https://doi.org/10.1016/j.cllc.2023.07.003 [IF 2022: 3.6]
  26. Parisi S, Ferini G, Lillo S, Brogna A, Chillari F, Ferrantelli G, Settineri N, Santacaterina A, Platania A, Leotta S, Casablanca G, Russo A, Pontoriero A, Adamo V, Minutoli F, Bottari A, Cacciola A, Pergolizzi S. Stereotactic boost on residual disease after external-beam irradiation in clinical stage III non-small cell lung cancer: mature results of stereotactic body radiation therapy post radiation therapy (SBRTpostRT) study. Radiol Med. 2023 Jun 9. doi: 10.1007/s11547-023-01659-w. Epub ahead of print. PMID: 37294366. [IF 2021: 6.313]
  27. Rolfo C, Russo A. Exploiting the Full Potential of Novel Agents Targeting EGFR Exon 20 Insertions in Advanced NSCLC: Next-Generation Sequencing Outperforms Polymerase Chain Reaction–Based Testing. Journal of Thoracic Oncology 2023;18:674–7. https://doi.org/10.1016/j.jtho.2023.02.020 [IF 2022: 20.4].
  28. Rolfo C, Russo A, Malapelle U. The next frontier of early lung cancer and minimal residual disease detection: is multiomics the solution? EBioMedicine 2023;92:104605. https://doi.org/10.1016/j.ebiom.2023.104605. [IF 2022: 11.1]
  29. Cortellini A, D’Alessio A, Cleary S, Buti S, Bersanelli M, Bordi P, Tonini G, Vincenzi B, Tucci M, Russo A, Pantano F, Russano M, Stucci LS, Sergi MC, Falconi M, Zarzana MA, Santini D, Spagnolo F, Tanda ET, Rastelli F, Giorgi FC, Pergolesi F, Giusti R, Filetti M, Lo Bianco F, Marchetti P, Botticelli A, Gelibter A, Siringo M, Ferrari M, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Ghidini M, Nigro O, Grossi F, De Tursi M, Di Marino P, Queirolo P, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Spoto C, Vitale MG, Cannita K, Gennari A, Morganstein DL, Mallardo D, Nibid L, Sabarese G, Brunetti L, Perrone G, Ascierto PA, Ficorella C, Pinato DJ. Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer. Clin Cancer Res. 2023 May 1:CCR-22-3116. doi: 10.1158/1078-0432.CCR-22-3116. Epub ahead of print. PMID: 37125965. [IF 2022: 11.5]
  30. Chamorro DF, Cardona AF, Rodríguez J, Ruiz-Patiño A, Arrieta O, Moreno-Pérez DA, Rojas L, Zatarain-Barrón ZL, Ardila DV, Viola L, Recondo G, Blaquier JB, Martín C, Raez L, Samtani S, Ordóñez-Reyes C, Garcia-Robledo JE, Corrales L, Sotelo C, Ricaurte L, Cuello M, Mejía S, Jaller E, Vargas C, Carranza H, Otero J, Archila P, Bermudez M, Gamez T, Russo A, Malapelle U, de Miguel Perez D, de Lima VCC, Freitas H, Saldahna E, Rolfo C, Rosell R; CLICaP. Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study. Target Oncol. 2023 Apr 5. doi: 10.1007/s11523-023-00955-9. Epub ahead of print. PMID: 37017806. [IF 2021: 4.897]
  31. Lacquaniti A, Campo S, Russo A, Adamo V, Monardo P. Tolvaptan resistance is related with a short-term poor prognosis in patients with lung cancer and syndrome of inappropriate anti-diuresis. G Ital Nefrol. 2023 Feb 27;40(1):2023-vol1. PMID: 36883921.
  32. Rolfo C, Russo A. Moving Forward Liquid Biopsy in Early Liver Cancer Detection. Cancer Discov. 2023 Mar 1;13(3):532-534. doi: 10.1158/2159-8290.CD-22-1439. PMID: 36855918. [IF 2021: 38.272]
  33. Rolfo C, Malapelle U, Russo A. Skipping or Not Skipping? That’s the Question! An Algorithm to Classify Novel MET Exon 14 Variants in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2023 Feb;7:e2200674. doi: 10.1200/PO.22.00674. PMID: 36848608. [IF 2021: 5.479]
  34. Puliafito I, Chillari F, Russo A, Cantale O, Sciacca D, Castorina L, Colarossi C, Franchina T, Vitale MP, Ricciardi GRR, Adamo V, Esposito F and Giuffrida D. Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis. Front. Endocrinol. 2023. 14:1065599. doi: 10.3389/fendo.2023.1065599 [IF 2022: 5.2]
  35. Aldea M, Marinello A, Duruisseaux M, Zrafi W, Conci N, Massa G, Metro G, Monnet I, Gomez PI, Tabbo F, Bria E, Guisier F, Vasseur D, Lindsay CR, Ponce S, Cousin S, Citarella F, Fallet V, Minatta JN, Eisert A, de Saint Basile H, Audigier-Valette C, Mezquita L, Calles A, Mountzios G, Tagliamento M, Masip JR, Raimbourg J, Terrisse S, Russo A, Cortinovis D, Rochigneux P, Pinato DJ, Cortellini A, Leonce C, Gazzah A, Ghigna M-R, Ferrara R, Dall’Olio FG, Passiglia F, Ludovini V, Barlesi F, Felip E, Planchard D, Besse B. RET-MAP: An international multi-center study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion. Journal of Thoracic Oncology (2023), doi: https://doi.org/10.1016/j.jtho.2022.12.018 [IF 2022: 20.4].
  36. Malapelle U, Parente P, Pepe F, Di Micco MC, Russo A, Clemente C, Graziano P, Rossi A. B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer? Int J Mol Sci. 2022 Dec 16;23(24):16077. doi: 10.3390/ijms232416077. PMID: 36555714; PMCID: PMC9788608. [IF 2021: 6.208]
  37. de Miguel-Perez D, Russo A, Gunasekaran M, Buemi F, Hester L, Fan X, Carter-Cooper BA, Lapidus RG, Peleg A, Arroyo-Hernández M, Cardona AF, Naing A, Hirsch FR, Mack PC, Kaushal S, Serrano MJ, Adamo V, Arrieta O, Rolfo C. Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer. Cancer. 2023 Feb 15;129(4):521-530. doi: 10.1002/cncr.34576. Epub 2022 Dec 9. PMID: 36484171. [IF 2021: 6.921].
  38. Cammarata G, de Miguel-Perez D, Russo A, Peleg A, Dolo V, Rolfo C, Taverna S. Emerging noncoding RNAs contained in extracellular vesicles: rising stars as biomarkers in lung cancer liquid biopsy. Ther Adv Med Oncol. 2022, Vol. 14: 1–20. DOI: 10.1177/17588359221131229 [IF 2021: 5.485]
  39. Zhang B, Liang H, Liu W, Zhou X, Qiao S, Li F, Tian P, Li C, Ma Y, Zhang H, Zhang Z, Nanjo S, Russo A, Puig-Butillé JA, Wu K, Wang C, Zhao X, Yue D. A novel approach for the non-invasive diagnosis of pulmonary nodules using low-depth whole-genome sequencing of cell-free DNA. Transl Lung Cancer Res. 2022 Oct;11(10):2094-2110. doi: 10.21037/tlcr-22-647. PMID: 36386459; PMCID: PMC9641036. [IF 2022: 4].
  40. Rolfo C, Malapelle U, Russo A. Expanding the Full Potential of Liquid Biopsies for Lung Cancer Patients. Cancer Res. 2022 Aug 16;82(16):2826-2828. doi: 10.1158/0008-5472.CAN-22-2109. PMID: 35971678. [IF 2021: 13.312]
  41. Malapelle U, Pisapia P, Pepe F, Russo G, Buono M, Russo A, Gomez J, Khorshid O, Mack PC, Rolfo C, Troncone G The Evolving Role of Liquid Biopsy in Lung Cancer. Lung Cancer 2022. https://doi.org/10.1016/j.lungcan.2022.08.004 [IF 2022: 5.3]
  42. Pisapia P, L’Imperio V, Galuppini F, Sajjadi E, Russo A, Cerbelli B, Fraggetta F, d’Amati G, Troncone G, Fassan M, Fusco N, Pagni F, Malapelle U. The evolving landscape of Anatomic Pathology. Crit Rev Oncol Hematol. 2022 Aug 4:103776. doi: 10.1016/j.critrevonc.2022.103776. Epub ahead of print. PMID: 35934262. [IF 2022: 6.2]
  43. Crocetto F, Russo G, Di Zazzo E, Pisapia P, Mirto BF, Palmieri A, Pepe F, Bellevicine C, Russo A, La Civita E, Terracciano D, Malapelle U, Troncone G, Barone B. Liquid Biopsy in Prostate Cancer Management—Current Challenges and Future Perspectives. Cancers. 2022; 14(13):3272. https://doi.org/10.3390/cancers14133272. [IF 2021: 6.575]
  44. Rojas L, Mayorga D, Ruiz-Patiño A, Rodríguez J, Cardona AF, Archila P, Avila J, Bravo M, Ricaurte L, Sotelo C, Arrieta O, Zatarain-Barrón ZL, Carranza H, Otero J, Vargas C, Barrón F, Corrales L, Martín C, Recondo G, Pino LE, Bermudez MA, Gamez T, Ordoñez-Reyes C, García-Robledo JE, de Lima VC, Freitas H, Santoyo N, Malapelle U, Russo A, Rolfo C, Rosell R. Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors. ESMO Open. 2022; 7(4). https://doi.org/10.1016/j.esmoop.2022.100500 [IF 2022: 7.3]
  45. Cordeiro de Lima VC, Corassa M, Saldanha E, Freitas H, Arrieta O, Raez L, Samtani S, Ramos M, Rojas C, Burotto M, Chamorro DF, Recondo G, Ruiz-Patiño A, Más L, Zatarain-Barrón L, Mejía S, Nicolas Minata J, Martín C, Bautista Blaquier J, Motta Guerrero R, Aliaga-Macha C, Carracedo C, Ordóñez- Reyes C, Esteban Garcia-Robledo J, Corrales L, Sotelo C, Ricaurte L, Santoyo N, Cuello M, Jaller E, Rodríguez J, Archila P, Bermudez M, Gamez T, Russo A, Viola L, Malapelle U, de Miguel Perez D, Rolfo C, Rosell R, Cardona AF. STK11 and KEAP1 mutations in non-small cell lung cancer patients: descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP). Lung Cancer. 2022. https://doi.org/10.1016/j.lungcan.2022.06.010 [IF 2022: 5.3]
  46. Cardona AF, Ruiz-Patiño A, Recondo G, Martín C, Raez L, Samtani S, Minata JN, Blaquier JB, Enrico D, Burotto M, Ordóñez-Reyes C, Chamorro DF, Garcia-Robledo JE, Corrales L, Zatarain-Barrón ZL, Más L, Sotelo C, Ricaurte L, Santoyo N, Cuello M, Mejía S, Jaller E, Vargas C, Carranza H, Otero J, Rodríguez J, Archila P, Bermudez M, Gamez T, de Lima VC, Freitas H, Russo A, Polo C, Malapelle U, Perez D de M, Rolfo C, Viola L, Rosell R, Arrieta O Mechanisms of Resistance to first-line Osimertinib in Hispanic patients with EGFR mutant non-small cell lung cancer (FRESTON-CLICaP). Clinical Lung Cancer. 2022 Jun 17; https://doi.org/10.1016/j.cllc.2022.06.001 [IF 2022: 3.6]
  47. Ordóñez-Reyes C, Garcia-Robledo JE, Chamorro DF, Mosquera A, Sussmann L, Ruiz-Patiño A, Arrieta O, Zatarain-Barrón L, Rojas L, Russo A, de Miguel-Perez D, Rolfo C, Cardona AF. Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question. Pharmaceutics. 2022; 14(6):1243. https://doi.org/10.3390/pharmaceutics14061243 [IF 2021: 6.525]
  48. de Miguel-Perez D, Russo A, Arrieta O, Ak M, Barron F, Gunasekaran M, Mamindla P, Lara-Mejia L, Peterson CB, Er ME, Peddagangireddy V, Buemi F, Cooper B, Manca P, Lapidus RG, Hsia RC, Cardona AF, Naing A, Kaushal S, Hirsch FR, Mack PC, Serrano MJ, Adamo V, Colen RR, Rolfo C. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. J Exp Clin Cancer Res. 2022 Jun 2;41(1):186. doi: 10.1186/s13046-022-02379-1. PMID: 35650597 [IF 2022: 11.3]
  49. Catania C, Piperno G, Russo A, Greco C, Agustoni F, Scotti V, Proto C, Sangalli C, Patani F, Santacaterina A, Di Pietro Paolo M, Agresti B, Filippi AR, Ramella S. Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era. Crit Rev Oncol Hematol. 2022 Apr 21:103684. doi: 10.1016/j.critrevonc.2022.103684. Epub ahead of print. PMID: 35462031 [IF 2022: 6.2]
  50. Cantini L, Mentrasti G, Lo Russo G, Signorelli D, Pasello G, Rijavec E, Russano M, Antonuzzo L, Rocco D, Giusti R, Adamo V, Genova C, Tuzi A, Morabito A, Gori S, La Verde N, Chiari R, Cortellini A, Cognigni V, Pecci F, Indini A, De Toma A, Zattarin E, Oresti S, Pizzutilo EG, Frega S, Erbetta E, Galletti A, Citarella F, Fancelli S, Caliman E, Della Gravara L, Malapelle U, Filetti M, Piras M, Toscano G, Zullo L, De Tursi M, Di Marino P, D’Emilio V, Cona MS, Guida A, Caglio A, Salerno F, Spinelli G, Bennati C, Morgillo F, Russo A, Dellepiane C, Vallini I, Sforza V, Inno A, Rastelli F, Tassi V, Nicolardi L, Pensieri V, Emili R, Roca E, Migliore A, Galassi T, Bruno Rocchi ML, Berardi R, Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario, ESMO Open (2022), doi: https://doi.org/10.1016/j.esmoop.2022.100406 [IF 2022: 7.3]
  51. Garcia-Robledo JE, Rosell R, Ruíz-Patiño A, Sotelo C, Arrieta O, Zatarain-Barrón L, Ordoñez C, Jaller E, Rojas L, Russo A, de Miguel-Pérez D, Rolfo C, Cardona AF. KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block. Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666211066064. doi: 10.1177/17534666211066064. PMID: 35098800 [IF 2021: 5.158]
  52. Cortellini A, Giusti R, Filetti M, Citarella F, Adamo V, Santini D, Buti S, Nigro O, Cantini L, Di Maio M, Aerts JGJV, Bria E, Bertolini F, Ferrara MG, Ghidini M, Grossi F, Guida A, Berardi R, Morabito A, Genova C, Mazzoni F, Antonuzzo L, Gelibter A, Marchetti P, Chiari R, Macerelli M, Rastelli F, Della Gravara L, Gori S, Tuzi A, De Tursi M, Di Marino P, Mansueto G, Pecci F, Zoratto F, Ricciardi S, Migliorino MR, Passiglia F, Metro G, Spinelli GP, Banna GL, Friedlaender A, Addeo A, Ficorella C, Porzio G, Tiseo M, Russano M, Russo A, Pinato DJ. High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. J Hematol Oncol. 2022 Jan 21;15(1):9. doi: 10.1186/s13045-022-01226-2. PMID: 35062993 [IF 2021: 23.168]
  53. Rodriguez-Martinez A, Simon-Saez I, Perales S, Garrido-Navas C, Russo A, de Miguel-Perez D, Puche-Sanz I, Alaminos C, Ceron J, Lorente JA, Molina MP, Gonzalez C, Cristofanilli M, Ortigosa-Palomo A, Real PJ, Rolfo C, Serrano MJ. Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior. Theranostics. 2022 Feb 7;12(5):2150-2161. doi: 10.7150/thno.64252. PMID: 35265204; PMCID: PMC8899588. [IF 2021: 11.600]
  54. Ruiz-Patiño A, Rodríguez J, Cardona, A.F., Ávila, J., Archila, P., Carranza, H., Vargas, C., Otero, J., Arrieta, O., Zatarain-Barrón, L., Sotelo, C., Ordoñez, C., García-Robledo, J.E., Rojas, L., Bermúdez, M., Gámez, T., Mayorga, D., Corrales, L., Martín, C., Recondo, G., Mas, L., Samtani, S., Ricaurte, L., Malapelle, U., Russo A, Barrón, F., Santoyo, N., Rolfo, C., Rosell, R., 2022. p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics. Translational Oncology 15, 101276. https://doi.org/10.1016/j.tranon.2021.101276 [IF 2021: 4.803]
  55. Rolfo C, Meshulami N, Russo A, Krammer F, Garcia-Sastre A, Mack PC, Gomez JE, Bhardwaj N, Benyounes A, Sirera R, Moore A, Rohs N, Henschke CI, Yankelevitz D, King J, Shyr Y, Bunn Jr PA, Minna JD, Hirsch FR, Lung Cancer and SARS-CoV-2 infection: Identifying important knowledge gaps for investigation. Journal of Thoracic Oncology (2021), doi: https:// doi.org/10.1016/j.jtho.2021.11.001. [IF 2022: 20.4].
  56. Addeo A, Friedlaender A, Giovannetti E, Russo A, de Miguel-Perez D, Arrieta O, Cardona AF, Rolfo C. A New Generation of Vaccines in the Age of Immunotherapy. Curr Oncol Rep. 2021 Nov 4;23(12):137. doi: 10.1007/s11912-021-01130-x. PMID: 34735649; PMCID: PMC8566658. [IF 2021: 5.945]
  57. Rosas D, Raez LE, Russo A, Rolfo C. Neuregulin 1 Gene (NRG1). A Potentially New Targetable Alteration for the Treatment of Lung Cancer. Cancers. 2021; 13(20):5038. https://doi.org/10.3390/cancers13205038 [IF 2021: 6.575]
  58. Malapelle U, Pisapia P, Addeo A, Arrieta O, Bellosillo B, Cardona AF, Cristofanilli M, de Miguel-Perez D, Denninghoff V, Durán I, Jantus-Lewintre E, Nuzzo PV, O’Byrne K, Pauwels P, Pickering EM, Raez LE, Russo A, Serrano MJ, Gandara DR, Troncone G, Rolfo C. Liquid Biopsy from research to clinical practice: focus on Non-Small Cell Lung Cancer. Expert Rev Mol Diagn. 2021 Sep 27. doi: 10.1080/14737159.2021.1985468. [IF 2022: 5.1].
  59. Friedlaender A, Subbiah V, Russo A, Banna GL, Malapelle U, Rolfo C, Addeo A. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nat Rev Clin Oncol. 2022 Jan;19(1):51-69. doi: 10.1038/s41571-021-00558-1. Epub 2021 Sep 24. Erratum in: Nat Rev Clin Oncol. 2021 Oct 5;: PMID: 34561632. [IF 2021: 65.011]
  60. Gabay C, Russo A, Raez LE, Rolfo Cervetto C. Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care? Expert Review of Anticancer Therapy 2021. doi:10.1080/14737140.2021.1982387 [IF 2022: 3.3]
  61. Rolfo C, Drilon A, Hong D, McCoach C, Dowlati A, Lin JJ, Russo A, Schram AM, Liu SV, Nieva JJ, Nguyen T, Eshaghian S, Morse M, Gettinger S, Mobayed M, Goldberg S, Araujo-Mino E, Vidula N, Bardia A, Subramanian J, Sashital D, Stinchcombe T, Kiedrowski L, Price K, Gandara DR. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. Br J Cancer 2021. https://doi.org/10.1038/s41416-021-01536-1 [IF 2022: 8.8]
  62. Russano M, Cortellini A, Giusti R, Russo A, Zoratto F, Rastelli F, Gelibter A, Chiari R, Nigro O, De Tursi M, Bracarda S, Gori S, Grossi F, Bersanelli M, Calvetti L, Di Noia V, Scartozzi M, Di Maio M, Bossi P, Falcone A, Citarella F, Pantano F, Ficorella C, Filetti M, Adamo V, Veltri E, Pergolesi F, Occhipinti MA, Nicolardi L, Tuzi A, Di Marino P, Macrini S, Inno A, Ghidini M, Buti S, Aprile G, Lai E, Audisio M, Intagliata S, Marconcini R, Brocco D, Porzio G, Piras M, Rijavec E, Simionato F, Natoli C, Tiseo M, Vincenzi B, Tonini G, Santini D. Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. Cancer Immunol Immunother. 2021 Aug 31. doi: 10.1007/s00262-021-03045-9. Epub ahead of print. PMID: 34462870. [IF 2021 6.630]
  63. Blaquier JB, Cardona AF, Russo A, Rolfo C, Recondo G. Next-generation sequencing using liquid biopsy in the care of patients with ALK-rearranged non-small cell lung cancer: a focus on lorlatinib. Precis Cancer Med 2021. doi: 10.21037/pcm-20-59
  64. Cortinovis D, Malapelle U, Pagni F, Russo A, Banna GL, Sala E, Rolfo C. Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review. Transl Lung Cancer Res 2021. doi: 10.21037/ tlcr-20-1067 [IF 2022: 4].
  65. Zhang X, Tian D, Chen Y, Chen C, He LN, Zhou Y, Li H, Lin Z, Chen T, Wang Y, Russo A, Nadal E, Passiglia F, Soo RA, Watanabe S, Moran T, Oh IJ, Fu S, Hong S, Zhang L. Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy. Transl Lung Cancer Res 2021. doi: 10.21037/tlcr-21-455 [IF 2022: 4].
  66. Santini D, Zeppola T, Russano M, Citarella F, Anesi C, Buti S, Tucci M, Russo A, Sergi MC, Adamo V, Stucci LS, Bersanelli M, Mazzaschi G, Spagnolo F, Rastelli F, Giorgi FC, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Siringo M, Ferrari M, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Ghidini M, Nigro O, Grossi F, De Tursi M, Di Marino P, Pala L, Queirolo P, Bracarda S, Macrini S, Gori S, Inno A, Zoratto F, Tanda ET, Mallardo D, Vitale MG, Talbot T, Ascierto PA, Pinato DJ, Ficorella C, Porzio G, Cortellini A. PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. J Transl Med. 2021 Jun 24;19(1):270. doi: 10.1186/s12967-021-02937-9. [IF 2021: 8.440]
  67. Buti S, Bersanelli M, Perrone F, Bracarda S, Di Maio M, Giusti R, Nigro O, Cortinovis DL, Aerts JGJV, Guaitoli G, Barbieri F, Ferrara MG, Bria E, Grossi F, Bareggi C, Berardi R, Torniai M, Cantini L, Sforza V, Genova C, Chiari R, Rocco D, Della Gravara L, Gori S, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Filetti M, Citarella F, Russano M, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Follador A, Bisonni R, Tuzi A, Minuti G, Landi L, Ricciardi S, Migliorino MR, Tabbò F, Olmetto E, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Addeo A, Friedlaender A, Cannita K, Porzio G, Ficorella C, Carmisciano L, Pinato DJ, Mazzaschi G, Tiseo M, Cortellini A. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. Eur J Cancer. 2021 Jun;150:224-231. doi: 10.1016/j.ejca.2021.03.041. Epub 2021 May 3. PMID: 33934059 [IF 2021: 10.002].
  68. Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis DL, Aerts JG, Guaitoli G, Barbieri F, Giusti R, Ferrara MG, Bria E, D’Argento E, Grossi F, Rijavec E, Guida A, Berardi R, Torniai M, Sforza V, Genova C, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Della Gravara L, Inno A, Michele T, Grassadonia A, Di Marino P, Mansueto G, Zoratto F, Filetti M, Santini D, Citarella F, Russano M, Cantini L, Tuzi A, Bordi P, Minuti G, Landi L, Ricciardi S, Migliorino MR, Passiglia F, Bironzo P, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Friedlaender A, Addeo A, Cannita K, Ficorella C, Porzio G, Pinato DJ. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021 Apr;9(4):e002421. doi: 10.1136/jitc-2021-002421 [IF 2022: 10.9]
  69. Denninghoff V, Russo A, de Miguel-Pérez D, Malapelle U, Benyounes A, Gittens A, Cardona AF, Rolfo C. Small Cell Lung Cancer: State of the Art of the Molecular and Genetic Landscape and Novel Perspective. Cancers (Basel). 2021 Apr 6;13(7):1723. doi: 10.3390/cancers13071723 [IF 2021: 6.575]
  70. Pisapia P, Costa JL, Pepe F, Russo G, Gragnano G, Russo A, Iaccarino A, de Miguel-Perez D, Serrano MJ, Denninghoff V, Quagliata L, Rolfo C, Malapelle U. Next Generation Sequencing for liquid biopsy based testing in Non-Small Cell Lung Cancer in 2021. Crit Rev Oncol Hematol. 2021 Mar 26:103311. doi: 10.1016/j.critrevonc.2021.103311. Online ahead of print. [IF 2022: 6.2]
  71. Cortellini A, Cannita K, Tiseo M, Cortinovis DL, Aerts JGJV, Baldessari C, Giusti R, Ferrara MG, D’Argento E, Grossi F, Guida A, Berardi R, Morabito A, Genova C, Antonuzzo L, Mazzoni F, De Toma A, Signorelli D, Gelibter A, Targato G, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Filetti M, Bracarda S, Citarella F, Russano M, Cantini L, Nigro O, Buti S, Minuti G, Landi L, Ricciardi S, Migliorino MR, Natalizio S, Simona C, De Filippis M, Metro G, Adamo V, Russo A, Spinelli GP, Di Maio M, Banna GL, Friedlaender A, Addeo A, Pinato DJ, Ficorella C, Porzio G.Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. Eur J Cancer. 2021;148:24-35. doi:https://doi.org/10.1016/j.ejca.2021.02.005 [IF 2021: 10.002].
  72. Rodríguez J, Avila J, Rolfo C, Ruíz-Patiño A, Russo A, Ricaurte L, Ordóñez-Reyes C, Arrieta O, Zatarain-Barrón ZL, Recondo G, Cardona AF. When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review. Oncol Ther. 2021 Mar 10. doi: 10.1007/s40487-021-00144-6. Epub ahead of print. PMID: 33689160.
  73. Buti S, Bersanelli M, Perrone F, Tiseo M, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Pergolesi F, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Ferrari M, Vitale MG, Nicolardi L, Chiari R, Rijavec E, Nigro O, Tuzi A, De Tursi M, Di Marino P, Conforti F, Queirolo P, Bracarda S, Macrini S, Gori S, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Santoni M, Patruno L, Porzio G, Ficorella C, Pinato DJ, Ascierto PA, Cortellini A, Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. Eur J Cancer. 2021 Jan 1;142:18–28 doi: 10.1016/j.ejca.2020.09.033. [IF 2021: 10.002].
  74. Cortellini A, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Bisonni R, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Bareggi C, Nigro O, Tuzi A, De Tursi M, Petragnani N, Pala L, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Pinato DJ, Porzio G, Ficorella C, Ascierto PA. Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. J Immunother Cancer. 2020 Nov;8(2):e001361. doi: 10.1136/jitc-2020-001361 [IF 2022: 10.9]
  75. Rossi G, Barabino E, Fedeli A, Ficarra G, Coco S, Russo A, Adamo V, Buemi F, Zullo L, Dono M, De Luca G, Longo L, Dal Bello MG, Tagliamento M, Alama A, Cittadini G, Pronzato P, Genova C. Radiomic detection of EGFR mutations in NSCLC. Cancer Res. 2020 Nov 4:canres.0999.2020. doi: 10.1158/0008-5472.CAN-20-0999. Epub ahead of print. PMID: 33148663 [IF 2021: 13.312]
  76. Passaro A, Malapelle U, Del Re M, Attili I, Russo A, Guerini-Rocco E, Fumagalli C, Pisapia P, Pepe F, De Luca C, Cucchiara F, Troncone G, Danesi R, Spaggiari L, De Marinis F, Rolfo C. Understanding EGFR heterogeneity in lung cancer. ESMO Open. 2020; 5, e000919. https://doi.org/10.1136/esmoopen-2020-000919 [IF 2022: 7.3]
  77. Serrano MJ, Garrido-Navas MC, Diaz Mochon JJ, Cristofanilli M, Gil-Bazo I, Pauwels P, Malapelle U, Russo A, Lorente JA, Ruiz-Rodriguez AJ, Paz-Ares LG, Vilar E, Raez LE, Cardona AF, Rolfo C. Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy. Cancer Discov. 2020 https://doi.org/10.1158/2159-8290.CD-20-0466 [IF 2021: 38.272]
  78. Malapelle U, Rossi G, Pisapia P, Barberis M, Buttitta F, Castiglione F, Cecere FL, Grimaldi AM, Iaccarino A, Marchetti A, Massi D, Medicina D, Mele F, Minari R, Orlando E, Pagni F, Palmieri G, Righi L, Russo A, Tommasi S, Vermi W, Troncone G. BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients. Crit Rev Oncol Hematol. 2020; 156, 103118. https://doi.org/10.1016/j.critrevonc.2020.103118 [IF 2022: 6.2]
  79. Russo A, Cardona AF, Caglevic C, Manca P, Ruiz-Patiño A, Arrieta O, Rolfo C. Overcoming TKI resistance in fusion-driven NSCLC: New generation inhibitors and rationale for combination strategies. Transl Lung Cancer Res 2020. doi: 10.21037/tlcr-2019-cnsclc-06 [IF 2022: 4].
  80. Lopes AR, Russo A, Li AY, McCusker MG, Kroopnick JM, Scilla K, Mehra R, Rolfo C. Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report. Transl Lung Cancer Res 2020. http://dx.doi.org/10.21037/tlcr-20-408 [IF 2022: 4].
  81. Friedlaender A, Addeo A, Russo, A, Gregorc V, Cortinovis D, Rolfo CD. Targeted Therapies in Early Stage NSCLC: Hype or Hope? Int. J. Mol. Sci. 2020, 21, 6329. doi: 10.3390/ijms21176329 [IF 2021: 6.208].
  82. Rolfo C, Cardona AF, Ruiz-Patiño A, Ariza S, Zatarain-Barron L, Pino LE, Viola L, Russo A, Rojas L, Ricaurte L, Arrieta O, Atypical skin manifestations during immune checkpoint blockage in COVID19-infected lung cancer patients. J Thorac Oncol. 2020 Jul 9:S1556-0864(20)30543-8. doi: 10.1016/j.jtho.2020.06.019 [IF 2023: 20.4].
  83. Rolfo, C, Russo, A, de Miguel-Pérez, D. Speeding tumor genotyping during the SARS‐CoV‐2 outbreak through liquid biopsy. Cancer. 2020. https://doi.org/10.1002/cncr.32983 [IF 2021: 6.921]
  84. Ruiz-Patiño A, Arrieta O, Pino LE, Rolfo C, Ricaurte L, Recondo G, Zatarain-Barron ZL, Corrales L, Martín C, Barrón F, Vargas C, Carranza H, Otero J, Rodriguez J, Sotelo C, Viola L, Russo A, Rosell R, Cardona AF. Mortality and Advanced Support Requirement for Patients With Cancer With COVID-19: A Mathematical Dynamic Model for Latin America. JCO Global Oncology. 2020; 752–760. https://doi.org/10.1200/GO.20.00156
  85. Rolfo C, Russo A. Liquid biopsy for early stage lung cancer moves ever closer. Nat Rev Clin Oncol. 2020 May 26. doi: 10.1038/s41571-020-0393-z [IF 2021: 65.011].
  86. Nigro O, Pinotti G, De Galitiis F, Di Pietro FR, Giusti R, Filetti M, Bersanelli M, Lazzarin A, Bordi P, Catino A, Pizzutilo P, Galetta D, Marchetti P, Botticelli A, Scagnoli S, Russano M, Santini D, Torniai M, Berardi R, Ricciuti B, De Giglio A, Chiari R, Russo A, Adamo V, Tudini M, Silva RR, Bolzacchini E, Giordano M, Di Marino P, De Tursi M, Rijavec E, Ghidini M, Vallini I, Stucci LS, Tucci M, Pala L, Conforti F, Queirolo P, Tanda E, Spagnolo F, Cecchi F, Bracarda S, Macrini S, Santoni M, Battelli N, Fargnoli MC, Porzio G, Tuzi A, Suter MB, Ficorella C, Cortellini A. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. European Journal of Cancer. 2020;134:19-28. doi:10.1016/j.ejca.2020.04.025 [IF 2021: 10.002].
  87. Rolfo C, Cardona AF, Cristofanilli M, Paz-Ares L, Diaz Mochon JJ, Duran I, Raez LE, Russo A, Lorente JA, Malapelle U, Gil-Bazo I, Jantus-Lewintre E, Pauwels P, Mok T, Serrano MJ, 2020. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). Crit Rev Oncol Hematol. 2020 May 5;151:102978. doi: 10.1016/j.critrevonc.2020.102978 [IF 2022: 6.2]
  88. Rossi G, Russo A, Tagliamento M, Tuzi A, Nigro O, Vallome G, Sini C, Grassi M, Dal Bello MG, Coco S, Longo L, Zullo L, Tanda ET, Dellepiane C, Pronzato P, Genova C. Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. Cancers. 2020; 12(5):1125. doi: 10.3390/cancers12051125. [IF 2021: 6.575]
  89. Rolfo C, Russo A. HER2 Mutations in Non–Small Cell Lung Cancer: A Herculean Effort to Hit the Target. Cancer Discov. 2020;10:643. doi: 10.1158/2159-8290.CD-20-0225 [IF 2021: 38.272]
  90. Russo A, Lopes AR, McCusker MG, Garrigues SG, Ricciardi GR, Arensmeyer KE, Scilla KA, Mehra R, Rolfo C. New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1). Curr Oncol Rep. 2020 Apr 16;22(5):48. doi: 10.1007/s11912-020-00909-8 [IF 2021: 5.945]
  91. Russo A, Lopes AR, Scilla K, Mehra R, Adamo V, Oliveira J, Liu SV, Rolfo C. NTRK and NRG1 gene fusions in advanced non-small cell lung cancer (NSCLC). Precis Cancer Med 2020. doi: 10.21037/pcm.2020.03.02
  92. Zhang L, Zheng J, Ahmed R, Huang G, Reid J, Mandal R, Maksymuik A, Sitar DS, Tappia PS, Ramjiawan B, Joubert P, Russo A, Rolfo CD, Wishart DS. A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection. Cancers. 2020; 12(3):622. doi: 10.3390/cancers12030622 [IF 2021: 6.575]
  93. Pantano F, Russano M, Berruti A, Mansueto G, Migliorino MR, Adamo V, Aprile G, Gelibter A, Ficorella C, Falcone A, Russo A, Aieta M, Maio M, Martelli O, Barni S, Napolitano A, Roca E, Quadrini S, Iacono D, Russo A, Calvetti L, Occhipinti MA, Cortellini A, Vasile E, Passiglia F, Imperatori M, Calabrò L, Di Giacomo AM, Petrelli F, Pasquini G, Franchina T, Venditti O, Intagliata S, Galvano A, Vincenzi B, Tonini G, Santini D. Prognostic and predictive clinical factors in patients affected by Non-Small-Cell Lung Cancer receiving Nivolumab. Expert Opin Biol Ther 2020 Feb 03. https://doi.org/10.1080/14712598.2020.1724953 [Epub ahead of print] [IF 2023: 4.6]
  94. Russo A, Russano M, Franchina T, Migliorino MR, Aprile G, Mansueto G, Berruti A, Falcone A, Aieta M, Gelibter A, Russo A, Barni S, Maio M, Martelli O, Pantano F, Iacono D, Calvetti L, Quadrini S, Roca E, Vasile E, Imperatori M, Occhipinti M, Galvano A, Petrelli F, Calabrò L, Pasquini G, Intagliata S, Ricciardi GRR, Tonini G, Santini D, Adamo V. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. Adv Ther. 2020 Mar;37(3):1145-1155. doi: 10.1007/s12325-020-01229-w. [IF 2021: 4.070]
  95. Zhang P, Xiong X, Rolfo C, Du X, Zhang Y, Yang H, Russo A, Devenport M, Zhou P, Liu Y, Zheng P. Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies. Cancers. 2020; 12(2):284 . doi: 10.3390/cancers12020284. [IF 2021: 6.575]
  96. Russo A, Ron DA, Rasschaert M, Prenen H, Mehra R, Pawels P, Rolfo C. Is there a room for personalized medicine in small cell lung cancer (SCLC)? Remarkable activity of pazopanib in a refractory FGFR1-amplified ED-SCLC patient. JCO Precis Oncol. 2019;(3):1-8. doi:10.1200/PO.19.00243 [IF 2021: 5.479]
  97. de Miguel-Pérez D, Bayarri-Lara CI, Ortega FG, Russo A, Moyano Rodriguez MJ, Alvarez-Cubero MJ, Maza Serrano E, Lorente JA, Rolfo C, Serrano MJ. Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma. Cancers. 2019, 11, 1750. doi: 10.3390/cancers11111750. [IF 2021: 6.575]
  98. Li AY, McCusker MG, Russo A, Scilla KA, Gittens A, Arensmeyer K, Mehra R, Adamo V, Rolfo C. RET Fusions in Solid Tumors. Cancer Treat Rev. 2019 Oct 30;81:101911. doi: 10.1016/j.ctrv.2019.101911 [IF 2022: 11.8].
  99. Russo A, de Miguel Perez D, Gunasekaran M, Scilla K, Lapidus R, Cooper B, Mehra R, Adamo V, Malapelle U, Rolfo C. Liquid biopsy tracking of lung tumor evolutions over time. Expert Rev Mol Diagn. 2019 Dec;19(12):1099-1108. doi: 10.1080/14737159.2020.1680287. Epub 2019 Oct 16 [IF 2022: 5.1].
  100. Singhal S, Rolfo C, Maksymiuk AW, Tappia PS, Sitar DS, Russo A, Akhtar PS, Khatun N, Rahnuma P, Rashiduzzaman A, Ahmed Bux R, Huang G, Ramjiawan B. Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study. Cancers (Basel). 2019 Jul 29;11(8). pii: E1069. doi: 10.3390/cancers11081069 [IF 2021: 6.575]
  101. Russo A, Scilla KA, Rolfo C. Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities. A commentary of the 3-year follow-up of the KEYNOTE-001 trial. Transl Cancer Res 2019;8(Suppl 6):S598-S602. doi: 10.21037/tcr.2019.06.24 [IF 2022: 0.9].
  102. Scilla KA, Russo A, Rolfo C. Immunotherapy Use in Human Immunodeficiency Virus (HIV)-infected Non-small Cell Lung Cancer Patients: Current data. J Immunother Precis Oncol 2019;2:55-8. DOI:10.4103/JIPO.JIPO_13_19
  103. Rossi G, Pezzuto A, Sini C, Tuzi A, Citarella F, McCusker M, Nigro O, Tanda E, Russo A. Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario. Crit Rev Oncol Hematol. 2019;142: 26-34. doi: 10.1016/j.critrevonc.2019.07.005. [IF 2022: 6.2]
  104. McCusker MG, Russo A, Scilla KA, Mehra R, Rolfo C. How I treat ALK-positive non-small cell lung cancer. ESMO Open. 2019 Jul 20;4(Suppl 2):e000524. DOI: 10.1136/esmoopen-2019-000524 [IF 2022: 7.3]
  105. Russo A, Franchina T, Ricciardi GRR, Battaglia A, Picciotto M, Adamo V. Heterogeneous responses to Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: new insights and future perspectives in this complex clinical scenario. Int J Mol Sci. 2019;20(6). doi: 10.3390/ijms20061431. [IF 2021: 6.208]
  106. Sini C, Tuzi A, Rossi G, Russo A, Pezzuto A. Acquired resistance in oncogene-addicted non-small-cell lung cancer. Future Oncol. 2018;14(13s):29-40. doi: 10.2217/fon-2018-0097 [IF 2021: 3.674].
  107. Russo A, Franchina T, Ricciardi GRR, Toscano G, Schifano S, Lo Certo G, Battaglia A, Pantò E, Scaffidi Fonti M, Adamo V. The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy. Crit Rev Oncol Hematol. 2018; 130: 1-12. doi: 10.1016/j.critrevonc.2018.06.007 [IF 2022: 6.2]
  108. Russo A, Franchina T, Ricciardi GRR, Battaglia A, Scimone A, Adamo V. Immunotherapy challenges in brain metastases management of NSCLC patients: a case report. APMB – Atti della Accademia Peloritana dei Pericolanti Classe di Scienze Medico Biologiche. 2018; 106 (1): A6 (1-9).
  109. Russo A, Franchina T, Ricciardi GRR, Battaglia A, Scimone A, Berenato R, Giordano A, Adamo V. Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. J Cell Physiol. 2018;233(10):6337-6343. doi: 10.1002/jcp.26609 [IF 2021: 6.513].
  110. Ricciardi GRR, Russo A, FranchIna T, Schifano S, Mastroeni G, Santacaterina A, Adamo V. Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy. A case report and literature review. BMC Cancer. 2018;18(1):97. doi: 10.1186/s12885-018-3994-5 [IF 2021: 4.638].
  111. Picciotto M, Russo A, Guarini V, Santacaterina A, Franchina T. Trattamento del glioblastoma multiforme nell’anziano. Argomenti di Oncologia Geriatrica. 2017; 2 (4): 14-19.
  112. Russo A, Franchina T, Ricciardi GRR, Smiroldo V, Picciotto M, Zanghì M, Rolfo C, Adamo V. Third generation EGFR TKIs in EGFR-mutated NSCLC: where are we now and where are we going. Crit Rev Oncol Hematol. 2017;117:38-47. doi: 10.1016/j.critrevonc.2017.07.003 [IF 2022: 6.2]
  113. Franchina T, Russo A, Ricciardi GRR, Adamo V. Challenges and perspectives in the multidisciplinary management of well-differentiated lung neuroendocrine tumours: a case report. APMB – Atti della Accademia Peloritana dei Pericolanti – Classe di Scienze Medico-Biologiche. 2017; 105: A3(1-6). doi: 10.6092/1828-6550/APMB.105.1.2017.A3
  114. Picciotto M, Franchina T, Russo A, Ricciardi GRR, Provazza G, Sava S, Baldari S, Caffo O, Adamo V. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer. Expert Opin Pharmacother. 2017;18(9):899-908. doi: 10.1080/14656566.2017.1323875 [IF 2023: 3.3].
  115. Russo A, Franchina T, Ricciardi GR, Fanizza C, Scimone A, Chiofalo G, Giordano A, Adamo V. Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer. Oncotarget. 2017;8(5):8717-8725. doi: 10.18632/oncotarget.14427 [IF 2016: 5.168].
  116. Russo A, Franchina T, Ricciardi GRR, Adamo V. Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation. J Thorac Oncol. 2017; 12 (1): e6-e8. doi: 10.1016/j.jtho.2016.09.132 [IF 2023: 20.4].
  117. Franchina T, Russo A, Ricciardi GRR, Liguori G, Herberg A, Normanno N, Adamo V. Long time response with chemotherapy In ROS1 NSCLC patient with unusual metastatic site. Cancer Biol Ther. 2016 Oct 2;17(10):1089-1093. doi: 10.1080/15384047.2016.1219822 [IF 2021: 4.875].
  118. Ricciardi GRR, Franchina T, Russo A, Schifano S, Ferraro G, Adamo V. Nab-paclitaxel and Trastuzumab combination: a promising approach for the neoadjuvant treatment HER2 positive Breast Cancer? Onco Targets Ther. 2016; 9: 4351–4355. doi: 10.2147/OTT.S107930. [IF 2021: 4.345].
  119. Russo A, Franchina T, Ricciardi GR, Ferraro G, Scimone A, Bronte G, Russo A, Rolfo C, Adamo V. Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance. Expert Rev Anticancer Ther. 2016 Jun;16(6):615-23. doi: 10.1080/14737140.2016.1182427 [IF 2022: 3.3]
  120. Bronte G, Franchina T, Alù M, Sortino G, Celesia C, Passiglia F, Savio G, Laudani A, Russo A, Picone A, Rizzo S, De Tursi M, Gambale E, Bazan V, Natoli C, Blasi L, Adamo V, Russo A. The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status. Oncotarget. 2016;7(24):35803-35812. doi: 10.18632/oncotarget.8130 [IF 2016: 5.168].
  121. Russo A, Franchina T, Ricciardi GRR, Picone A, Ferraro G, Zanghì M, Toscano G, Giordano A, Adamo V. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget. 2015 Sep 29;6(29):26814-25. doi: 10.18632/oncotarget.4254. doi: 10.18632/oncotarget.4254 [IF 2016: 5.168].
  122. Ricciardi GR, Russo A, Franchina T, Ferraro G, Adamo V. Efficacy of nab-paclitaxel plus trastuzumab in a long survivor heavily pretreated HER2-positive breast cancer patient with brain metastases. Onco Targets Ther. 2015;8:289-94. doi: 10.2147/OTT.S74110 [IF 2021: 4.345].
  123. Ricciardi GR, Russo A, Franchina T, Ferraro G, Zanghì M, Picone A, Scimone A, Adamo V. HER2 & NSCLC: Beetween lights and shadows. J Thorac Oncol. 2014;9(12):1750-62. doi: 10.1097/JTO.0000000000000379 [IF 2023: 20.4].

B) co-autore dei seguenti capitoli di libri:

  1. Malapelle U, Russo A, Mack P, Hirsch FR, Rolfo C. Gene fusions. In: ESMO Handbook of Targeted Therapies and Precision Oncology. Edited by Iwona Lugowska, Sandra Misale, Raffaele Califano, and John B.A.G. Haanen. ESMO Handbook Series 2022
  2. Russo A, McCusker MG, Scilla KA, Arensmeyer KE, Mehra R, Adamo V, Rolfo C (2020). Immunotherapy in Lung Cancer: From a Minor God to the Olympus. In: Naing A., Hajjar J. (eds) Immunotherapy. Advances in Experimental Medicine and Biology, vol 1244. Springer, Cham. doi: 10.1007/978-3-030-41008-7_4. [IF 2021: 3.650]
  3. Franchina T, Ricciardi GRR, Russo A, Adamo V. (2021) Treatment Toxicity. In: Russo A., Peeters M., Incorvaia L., Rolfo C. (eds) Practical Medical Oncology Textbook. UNIPA Springer Series. Springer, Cham. https://doi.org/10.1007/978-3-030-56051-5_19
  4. Kaen DL, Minatta N, Russo A, Malapelle U, de Miguel-Pérez D, Rolfo C (2021) Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met? In: Naing A., Hajjar J. (eds) Immunotherapy. Advances in Experimental Medicine and Biology, vol 1342. Springer, Cham. https://doi.org/10.1007/978-3-030-79308-1_4 [IF 2021: 3.650]

Unità

Torna su